We are live on ! Find out more
LCM

Lynx1 Capital Management Portfolio holdings

AUM $633M
1-Year Est. Return 173.22%
This Fund
S&P 500
This Quarter Est. Return
+4.55%
1 Year Est. Return
+173.22%
3 Year Est. Return
+779.42%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$151M
AUM Growth
-$1.44M
Cap. Flow
+$3.01M
Cap. Flow %
1.99%
Top 10 Hldgs %
93.67%
Holding
25
New
7
Increased
1
Reduced
7
Closed
7

Top Buys

Rank Stock Value
1
STOK icon
Stoke Therapeutics
STOK
+$11.2M
2
AUTL
Autolus Therapeutics
AUTL
+$3.88M
3
CCCC icon
C4 Therapeutics
CCCC
+$3.11M
4
SLN
Silence Therapeutics
SLN
+$1.74M
5
GHRS icon
GH Research
GHRS
+$1.55M

Top Sells

Rank Stock Value
1
PRDS
Pardes Biosciences, Inc. Common Stock
PRDS
+$7.06M
2
ALPN
Alpine Immune Sciences Inc
ALPN
+$3.27M
3
CBAY
Cymabay Therapeutics
CBAY
+$2.8M
4
NGNE icon
Neurogene
NGNE
+$2.57M
5
CGEM icon
Cullinan Oncology
CGEM
+$1.24M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CABA icon
1
Cabaletta Bio
CABA
$439M
$32.1M 21.2%
2,106,000
-75,377
-3% -$1.03M
ALPN
2
DELISTED
Alpine Immune Sciences Inc
ALPN
$27.5M 18.21%
2,404,614
-265,858
-10% -$3.27M
MRUS
3
DELISTED
Merus
MRUS
$27.1M 17.94%
1,150,225
-2,300
-0.2% -$55.8K
CBAY
4
DELISTED
Cymabay Therapeutics
CBAY
$14.8M 9.8%
994,161
-210,889
-18% -$2.8M
TCRX icon
5
TScan Therapeutics
TCRX
$51.9M
$13.4M 8.85%
5,224,600
– –
GHRS icon
6
GH Research
GHRS
$1.87B
$11.1M 7.33%
1,103,178
+133,804
+14% +$1.55M
STOK icon
7
Stoke Therapeutics
STOK
$1.82B
$6.74M 4.46%
+1,710,154
New +$11.2M
AUTL
8
Autolus Therapeutics
AUTL
$386M
$3.18M 2.1%
+1,363,025
New +$3.88M
PVLA
9
Palvella Therapeutics
PVLA
$1.98B
$2.91M 1.93%
122,198
– –
KNTE
10
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$2.8M 1.85%
1,997,006
-51,730
-3% -$124K
SLN
11
Silence Therapeutics
SLN
$521M
$2.32M 1.53%
+235,787
New +$1.74M
NEUP
12
Neuphoria Therapeutics
NEUP
$19.7M
$2.2M 1.46%
+67,959
New +$1.46M
CCCC icon
13
C4 Therapeutics
CCCC
$376M
$1.9M 1.25%
+1,019,230
New +$3.11M
THRX
14
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$1.89M 1.25%
702,415
-54,594
-7% -$214K
NKTR icon
15
Nektar Therapeutics
NKTR
$2.39B
$1.05M 0.7%
+117,788
New +$1.13M
PASG icon
16
Passage Bio
PASG
$15.9M
$125K 0.08%
9,506
-48,861
-84% -$803K
ZURA icon
17
Zura Bio
ZURA
$497M
$65.5K 0.04%
+9,917
New +$66.3K
DBVT
18
DBV Technologies
DBVT
$807M
$24.8K 0.02%
1,827
– –
LONA
19
LeonaBio Inc
LONA
$69.4M
– –
-19,357
Closed -$571K
CGEM icon
20
Cullinan Oncology
CGEM
$1.05B
– –
-115,063
Closed -$1.24M
CMPS
21
Compass Pathways
CMPS
$1.52B
– –
-20,114
Closed -$167K
GPCR icon
22
Structure Therapeutics
GPCR
$3.49B
– –
-23,000
Closed -$956K
NGNE icon
23
Neurogene
NGNE
$696M
– –
-154,728
Closed -$2.57M
PHVS icon
24
Pharvaris
PHVS
$2.39B
– –
-21,225
Closed -$321K
PRDS
25
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
– –
-3,902,434
Closed -$7.06M

Similar funds

SWM
SilverOak Wealth Management Edina, Minnesota $632M AUM 18.6% 1-Year Est. Return
RFA
Rollins Financial Advisors New York City, New York $632M AUM 23.84% 1-Year Est. Return
WA
WFM Asia Road Town, Tortola, British Virgin Islands $632M AUM 14.51% 1-Year Est. Return
AMM
American Money Management Rancho Santa Fe, California $632M AUM 14.06% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
ACM
Arini Captial Management London, United Kingdom $634M AUM
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return

Lynx1 Capital Management's Q3 2023 Portfolio in Review

As of Q3 2023, Lynx1 Capital Management held 25 positions worth $151M, down 0.94% from $153M the previous quarter. Its ten largest holdings account for 94% of the portfolio.

Lynx1 Capital Management's Q3 2023 filing shows 7 new, 1 increased, 7 reduced and 7 closed positions. Its largest new stake was Stoke Therapeutics: 1,710,154 shares worth $6.74M. The largest sale was Pardes Biosciences, Inc. Common Stock, an estimated $7.06M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Lynx1 Capital Management's largest Q3 2023 buy was Stoke Therapeutics: 1,710,154 shares worth $6.74M.
  • Lynx1 Capital Management added most to GH Research in Q3 2023, an estimated $1.55M increase.
  • Lynx1 Capital Management's biggest Q3 2023 reduction was Alpine Immune Sciences Inc, cutting an estimated $3.27M.
  • Lynx1 Capital Management fully exited Pardes Biosciences, Inc. Common Stock in Q3 2023, selling an estimated $7.06M.
  • Lynx1 Capital Management's ten largest holdings make up 94% of its $151M portfolio in Q3 2023.
  • Lynx1 Capital Management opened 7 new positions and closed 7 in Q3 2023.
  • Lynx1 Capital Management's portfolio value fell 0.94% quarter-over-quarter to $151M.

Based on Lynx1 Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.